Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 9/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 5/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16983984 | 0.91 | CA1 (0.42) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL15502185 | 0.91 | CA1 (0.42) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL13672322 | 0.90 | CA1 (0.41) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL7353657 | 0.84 | CA1 (0.49) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL7360111 | 0.84 | CA1 (0.49) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL20557220 | 0.84 | CA1 (0.49) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL7704727 | 0.83 | PLA2G2C (0.46) | CTSKCTSS | |
| SCHEMBL1688831 | 0.82 | CTSK (0.46) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL16020434 | 0.82 | CYP1A2 (0.44) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL7693886 | 0.81 | ATM (0.65) | CTSKATMCTSSSYKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200656-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-12-05 | — | — | EP | disclosed |
| EP-2200656-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-12-05 | — | — | EP | disclosed |
| US-8323619-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-12-04 | — | — | US | disclosed |
| US-8323619-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-12-04 | — | — | US | disclosed |
| US-8323619-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-12-04 | — | — | US | disclosed |
| US-8202511-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-06-19 | — | — | US | disclosed |
| US-8202511-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-06-19 | — | — | US | disclosed |
| US-20100303734-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| US-20100303734-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| EP-2231200-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009071605-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009060021-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009060021-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009047319-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047319-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-04-16 | — | — | WO | disclosed |
| US-5952316-A | FOR TREATING AUTOIMMUNE DISEASES, E.G., RHEUMATIOD ARTHRITIS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-14 | — | — | US | disclosed |
| EP-0627406-B1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL (JP) | 1998-10-28 | — | — | EP | disclosed |
| US-5719176-A | 2-amino-1,3-propanediol compound and immunosuppressant | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-02-17 | — | — | US | disclosed |
| US-5604229-A | 2-amino-1,3-propanediol compound and immunosuppressant | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-02-18 | — | — | US | disclosed |
| EP-0627406-A1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100303734-A1 | CONTRAST AGENTS | C1R, CNKSR1, C5 | CA1 250/4885CA2 494/4885CA7 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.